Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Tramadol: From Its Origins to Its Final Exit — A Complete Journey Through the Body
Mohamad-Ali Salloum, PharmD • March 7, 2026
Share
1. Where It All Began — The History
From Laboratory Design to Market
Tramadol didn’t come from a plant or a century‑old apothecary recipe. It was engineered. German pharmaceutical company Grünenthal first synthesized tramadol in the 1960s, with its preparation formally published in 1965, and eventually launched it in 1977 under the brand name Tramal.
It entered the U.S. market in 1995 as Ultram, originally not a controlled substance. But as misuse reports increased, it was later moved into Schedule IV due to its abuse potential and opioid‑like effects.
At its core, tramadol was designed to be a “hybrid analgesic”—a medication that combines weak opioid activity with monoamine modulation (serotonin and norepinephrine). This duality is the key to understanding everything that happens next.
2. The Patient Swallows It — The Start of the Journey
Absorption — Entering the System
A patient takes an oral tramadol tablet for moderate pain. Now the real story begins.
Absorption: Tramadol is rapidly and almost completely absorbed, though its oral bioavailability (≈65–75%) is reduced by first‑pass metabolism in the liver. Peak levels usually occur within 1–2 hours.
Once in the bloodstream, only about 20% binds to plasma proteins, leaving plenty available for activity. It distributes widely throughout the body and crosses the blood–brain barrier, which is essential for its analgesic effects.
3. First‑Pass Metabolism — The Liver’s Critical Decision
Two Dominant Pathways
CYP2D6 → O‑desmethyltramadol (M1)
This is the active opioid metabolite. It binds much more strongly to μ‑opioid receptors than the parent drug and is more potent at producing analgesia.
CYP3A4 / CYP2B6 → N‑desmethyltramadol (M2)
Much less pharmacologically important.
Genetic impact (CYP2D6):
- A patient who is a poor metabolizer produces less M1 → weaker opioid effect.
- An ultrarapid metabolizer produces more M1 → stronger effects but higher risk of opioid toxicity.
So even before tramadol reaches its site of action, two patients taking the same dose may experience very different results.
4. Reaching the Brain — Where Pharmacodynamics Come Alive
Mechanism of Action (MOA)
A) Opioid Pathway — Powered by M1
M1 binds to μ‑opioid receptors in the brain and spinal cord. This reduces pain signal transmission and produces classic opioid analgesia.
B) Monoaminergic Pathway — Driven by Parent Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake. This strengthens descending inhibitory pain pathways in the spinal cord, enhancing analgesia.
- Dampening pain signals traveling upward
- Strengthening the brain’s own pain‑suppressing pathways
This is why tramadol can help in certain neuropathic pain profiles where pure opioids fail.
5. The Clinical Effect — What the Patient Feels
Onset and Duration
Pain relief begins at about 1 hour after ingestion and lasts around 6 hours for immediate‑release formulations. This depends not just on absorption but also on how efficiently the patient converts tramadol into its active M1 metabolite.
6. Side Effects — The Direct Consequences of Its Mechanisms
Key Risks and Mechanisms
A) Serotonin Syndrome
Because tramadol increases serotonin levels, using it with SSRIs, SNRIs, MAOIs, or CYP2D6 inhibitors can dangerously elevate serotonin.
Symptoms:
agitation, clonus, hyperreflexia, sweating, fever.
Mechanism:
excess serotonergic activity.
B) Seizures
Tramadol lowers the seizure threshold, especially at high doses or in combination with other pro‑convulsant drugs.
Mechanism:
monoaminergic stimulation + metabolite accumulation.
C) Respiratory Depression
Usually milder than strong opioids, but can be severe in:
- Ultrarapid CYP2D6 metabolizers
- Overdose
- Combined use with sedatives
D) Typical Opioid Effects
Nausea, vomiting, constipation, dizziness, somnolence, sweating, pruritus.
Mechanism:
μ‑receptor activation + central effects.
E) Pediatric Risks
Children <12 years — contraindicated.
Post‑tonsillectomy/adenoidectomy <18 years — avoid.
Reason:
genetically driven excessive formation of M1 → life‑threatening respiratory depression.
7. The Final Chapter — Excretion
How It Leaves the Body
After doing its job, tramadol leaves the body mainly through the kidneys.
- Elimination half‑life:
- Parent tramadol: ~6 hours
- M1 metabolite: ~6–7.5 hours
Renal impairment slows clearance, requiring dose adjustments for IR formulations and avoidance of ER in severe cases. Ultimately, the metabolites are excreted in the urine, completing the medication’s journey.
Putting It All Together
A Unified View
- History: engineered to be part opioid, part monoamine‑modulating analgesic.
- Absorption & PK: efficiently absorbed, heavily shaped by CYP2D6 genetics.
- Mechanism & PD: dual action — μ‑opioid + serotonin/norepinephrine reuptake inhibition.
- Side effects: predictable consequences of its mechanisms.
- Excretion: renal elimination determines how long it stays active.
This unified view helps pharmacy and medical students understand not just what tramadol does, but why it behaves the way it does inside the body.
1. Where It All Began — The History
From Laboratory Design to Market
Tramadol didn’t come from a plant or a century‑old apothecary recipe. It was engineered. German pharmaceutical company Grünenthal first synthesized tramadol in the 1960s, with its preparation formally published in 1965, and eventually launched it in 1977 under the brand name Tramal.
It entered the U.S. market in 1995 as Ultram, originally not a controlled substance. But as misuse reports increased, it was later moved into Schedule IV due to its abuse potential and opioid‑like effects.
At its core, tramadol was designed to be a “hybrid analgesic”—a medication that combines weak opioid activity with monoamine modulation (serotonin and norepinephrine). This duality is the key to understanding everything that happens next.
2. The Patient Swallows It — The Start of the Journey
Absorption — Entering the System
A patient takes an oral tramadol tablet for moderate pain. Now the real story begins.
Absorption: Tramadol is rapidly and almost completely absorbed, though its oral bioavailability (≈65–75%) is reduced by first‑pass metabolism in the liver. Peak levels usually occur within 1–2 hours.
Once in the bloodstream, only about 20% binds to plasma proteins, leaving plenty available for activity. It distributes widely throughout the body and crosses the blood–brain barrier, which is essential for its analgesic effects.
3. First‑Pass Metabolism — The Liver’s Critical Decision
Two Dominant Pathways
CYP2D6 → O‑desmethyltramadol (M1)
This is the active opioid metabolite. It binds much more strongly to μ‑opioid receptors than the parent drug and is more potent at producing analgesia.
CYP3A4 / CYP2B6 → N‑desmethyltramadol (M2)
Much less pharmacologically important.
Genetic impact (CYP2D6):
- A patient who is a poor metabolizer produces less M1 → weaker opioid effect.
- An ultrarapid metabolizer produces more M1 → stronger effects but higher risk of opioid toxicity.
So even before tramadol reaches its site of action, two patients taking the same dose may experience very different results.
4. Reaching the Brain — Where Pharmacodynamics Come Alive
Mechanism of Action (MOA)
A) Opioid Pathway — Powered by M1
M1 binds to μ‑opioid receptors in the brain and spinal cord. This reduces pain signal transmission and produces classic opioid analgesia.
B) Monoaminergic Pathway — Driven by Parent Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake. This strengthens descending inhibitory pain pathways in the spinal cord, enhancing analgesia.
- Dampening pain signals traveling upward
- Strengthening the brain’s own pain‑suppressing pathways
This is why tramadol can help in certain neuropathic pain profiles where pure opioids fail.
5. The Clinical Effect — What the Patient Feels
Onset and Duration
Pain relief begins at about 1 hour after ingestion and lasts around 6 hours for immediate‑release formulations. This depends not just on absorption but also on how efficiently the patient converts tramadol into its active M1 metabolite.
6. Side Effects — The Direct Consequences of Its Mechanisms
Key Risks and Mechanisms
A) Serotonin Syndrome
Because tramadol increases serotonin levels, using it with SSRIs, SNRIs, MAOIs, or CYP2D6 inhibitors can dangerously elevate serotonin.
Symptoms:
agitation, clonus, hyperreflexia, sweating, fever.
Mechanism:
excess serotonergic activity.
B) Seizures
Tramadol lowers the seizure threshold, especially at high doses or in combination with other pro‑convulsant drugs.
Mechanism:
monoaminergic stimulation + metabolite accumulation.
C) Respiratory Depression
Usually milder than strong opioids, but can be severe in:
- Ultrarapid CYP2D6 metabolizers
- Overdose
- Combined use with sedatives
D) Typical Opioid Effects
Nausea, vomiting, constipation, dizziness, somnolence, sweating, pruritus.
Mechanism:
μ‑receptor activation + central effects.
E) Pediatric Risks
Children <12 years — contraindicated.
Post‑tonsillectomy/adenoidectomy <18 years — avoid.
Reason:
genetically driven excessive formation of M1 → life‑threatening respiratory depression.
7. The Final Chapter — Excretion
How It Leaves the Body
After doing its job, tramadol leaves the body mainly through the kidneys.
- Elimination half‑life:
- Parent tramadol: ~6 hours
- M1 metabolite: ~6–7.5 hours
Renal impairment slows clearance, requiring dose adjustments for IR formulations and avoidance of ER in severe cases. Ultimately, the metabolites are excreted in the urine, completing the medication’s journey.
Putting It All Together
A Unified View
- History: engineered to be part opioid, part monoamine‑modulating analgesic.
- Absorption & PK: efficiently absorbed, heavily shaped by CYP2D6 genetics.
- Mechanism & PD: dual action — μ‑opioid + serotonin/norepinephrine reuptake inhibition.
- Side effects: predictable consequences of its mechanisms.
- Excretion: renal elimination determines how long it stays active.
References :
- American Chemical Society. Tramadol – Molecule of the Week Archive. December 16, 2014. [acs.org]
- DEA Diversion Control Division. Tramadol Drug & Chemical Evaluation Section Report. April 2025. [deadiversi....usdoj.gov]
- Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879‑923. [go.drugbank.com]
- Food and Drug Administration (FDA). ULTRAM® (tramadol hydrochloride) tablets label. 2004. [accessdata.fda.gov]
- Nickson C. Tramadol – CCC Pharmacology. Life in the Fast Lane; 2024. [litfl.com]
- DrugBank Online. Tramadol: Uses, Interactions, Mechanism of Action. DB00193. [go.drugbank.com]
- Food and Drug Administration (FDA). Tramadol Hydrochloride Tablets (DailyMed). 2023. [dailymed.nlm.nih.gov]
- Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries. 2015. [ncbi.nlm.nih.gov]
- Food and Drug Administration (FDA). Tramadol ER Capsules Label Information. 2010. [accessdata.fda.gov]
- EBM Consult. Mechanism for Tramadol‑Induced Serotonin Syndrome in Patients Taking SSRIs. 2017.
- Medsafe Pharmacovigilance. Serious Reactions with Tramadol: Seizures and Serotonin Syndrome. 2007.
- Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1–6.
- Medscape Reference. Ultram, ConZip (tramadol) dosing, indications, interactions. 2026.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
Explore the difference between Sensitivity and Specificity
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to Distinguish Correlation from Causation in Orthopaedic Research. J Arthroplasty. 2022;38(4):634‑637. [pmc.ncbi.nlm.nih.gov] Association of Health Care Journalists. Correlation vs. Causation. [healthjournalism.org] Rush J, Ajami M, Look K, Margolis A. Statistics Review Part 10: Causality and Confounding. J Pharm Soc Wis. [jpswi.org] Biostat Prime. Correlation vs Causation: Meaning, Differences & Examples. [biostatprime.com] Koopmans E, Schiller C. Understanding Causation in Healthcare: An Introduction to Critical Realism. Qual Health Res. 2022;32(8–9):1207–1214. [pmc.ncbi.nlm.nih.gov]
References: Very Big Brain. Somatic Memories: How Physical Sensations Trigger Past Memories and Emotions . 2023 Nov 26. [verybigbrain.com] Misattribution of arousal. Wikipedia . 2026. [en.wikipedia.org] Zimbardo P. The Misattribution of Arousal Study (Dutton & Aron) . 2026. [zimbardo.com] Higgins L. Why You Feel Anxious After Drinking Coffee . TIME. 2025 Nov 11. [time.com] Double KS. Metacognitive ability is associated with reduced emotion suppression . Scientific Reports. 2026 Jan 28. [nature.com] Merkebu J et al. What is metacognitive reflection? Front Educ. 2023 Apr 5. [researchgate.net] Meyers S et al. Cognitive Reappraisal is More Effective for Regulating Emotions than Moods . Affective Science. 2025 Jun 6. [link.springer.com]
Are they the same?
A Practical Guide for the Public.
Did you know that your emotions are just suggestions?
Short-form videos like Reels and TikTok rapidly trigger dopamine, stress, and attention circuits—discover how they impact your brain, mood, and focus, plus practical tips to restore balance.